Wednesday, December 16, 2020
Investor Ideas #Potcasts Episode 508, #Cannabis News and #Stocks on the Move; (TSX: $APHA.TO) (NASDAQ: $APHA) (NASDAQ: $TLRY) (OTC: $EDXC) (OTCQX: $INLB)
Investor Ideas #Potcasts Episode 508, #Cannabis News and #Stocks on the Move; (TSX: $APHA.TO) (NASDAQ: $APHA) (NASDAQ: $TLRY) (OTC: $EDXC) (OTCQX: $INLB)
Delta, Kelowna, BC, December 16, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/121620-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/12161APHA-TLRY-EDXC-INLB.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be looking at a few private and public company announcements.
Aphria Inc. (TSX: APHA) (Nasdaq: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, and Tilray, Inc. (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that they have entered into a definitive agreement to combine their businesses and create the world’s largest global cannabis company based on pro forma revenue. The deal is pursuant to a plan of arrangement under the Business Corporations Act (Ontario), and the implied pro forma equity value of the Combined Company is approximately C$5.0 billion (US$3.9 billion), based on the share price of Aphria and Tilray at the close of market on December 15, 2020. Following the completion of the Arrangement, the Combined Company will have principal offices in the United States (New York and Seattle), Canada (Toronto, Leamington and Vancouver Island), Portugal and Germany, and it will operate under the Tilray corporate name with shares trading on NASDAQ under ticker symbol "TLRY".
The Combined Company, supported by low-cost, state-of-the-art cultivation, processing, and manufacturing facilities, will have a complete portfolio of branded Cannabis 2.0 products in Canada. Internationally, the Combined Company will be well-positioned to pursue growth opportunities with Aphria’s medical cannabis and distribution footprint in Germany, and Tilray’s European Union Good Manufacturing Practices low-cost cannabis production facility in Portugal, which has export capabilities and tariff-free access to the European Union to meet increasing global demand for medical cannabis. In the United States, the Combined Company will have a strong consumer packaged goods presence and infrastructure with two strategic pillars, including SweetWater Brewing Company, a cannabis lifestyle branded craft brewer, and Manitoba Harvest, a leading hemp food manufacturer and a pioneer in branded CBD and wellness products. The Combined Company is expected to have a strong, flexible balance sheet, cash balance and access to capital giving it the ability to accelerate growth and deliver attractive returns for stockholders.
Under the terms of the Arrangement, the shareholders of Aphria will receive 0.8381 shares of Tilray for each Aphria common share, while holders of Tilray shares will continue to hold their Tilray shares with no adjustment to their holdings. Upon the completion of the Arrangement, Aphria Shareholders will own approximately 62 percent of the outstanding Tilray Shares on a fully diluted basis, resulting in a reverse acquisition of Tilray, representing a premium of 23 percent based on the share price at market close on December 15, 2020 to Tilray shareholders. On a pro forma basis for the last twelve months reported by each company, the Combined Company would have had revenue of C$874 million (US$685 million).
The Combined Company will be led by a best-in-class management team and board of directors, with strong track records in consumer-packaged goods and cannabis experience internationally. Upon completion of the Arrangement, Aphria’s current Chairman and Chief Executive Officer, Irwin D. Simon, will lead the Combined Company as Chairman and Chief Executive Officer. The board of directors will consist of nine members, seven of which, including Mr. Simon, are current Aphria directors and two of which will be from Tilray, including Brendan Kennedy, and one of which is to be designated. Aphria and Tilray are confident that the leadership team and proposed board of directors of the Combined Company provides a strong foundation for the Combined Company to accelerate growth. Additional senior leadership positions at the Combined Company will be named at a later date.
"This is an exciting day for both companies including our 2,500 employees, for the cannabis industry, and for patients and consumers around the world. We are bringing together two world-class companies that share a culture of innovation, brand development and cultivation to enhance our Canadian, U.S., and international scale as we pursue opportunities for accelerated growth with the strength and flexibility of our balance sheet and access to capital," said Mr. Simon. "Our highly complementary businesses create a combined company with a leading branded product portfolio, including the most comprehensive Cannabis 2.0 product offerings for patients and consumers, along with significant synergies across our operations in Canada, Europe and the United States. Our business combination with Tilray aligns with our strategic focus and emphasis on our highest return priorities as we strive to generate value for all stakeholders."
"I am honored to work with Brendan Kennedy, a pioneer in the cannabis industry, and the Tilray team as they join forces with our talented employees at Aphria," continued Mr. Simon. "I look forward to leading the talented teams of both Aphria and Tilray as we seek to create a leading global cannabis and consumer packaged goods company with a portfolio of medical, wellness and adult-use brands consumers love."
Mr. Kennedy, Tilray’s Chief Executive Officer, commented, "We are thrilled to bring together two cannabis industry leaders. At this nascent stage of development and expansion of the global cannabis market, we believe companies with leading geographic scale, product range and brand expertise are most likely to benefit long-term. By leveraging our combined strengths and capabilities, we expect to be able to meet the needs of consumers more effectively all over the world and advance patient care. With a strong financial profile, low-cost production, leading brands, distribution network and unique partnerships, we believe the Combined Company will be well-positioned to deliver sustainable, attractive returns for stockholders. I look forward to working with Irwin and the Combined Company’s management team to make our consumer products more accessible around the world."
Emerald Bioscience, Inc. (OTCQB: EMBI), a preclinical biopharmaceutical company focused on developing proprietary molecules with strong clinical and commercial differentiation, announced the publication of a peer-reviewed paper reporting that THCVHS, the Company’s novel THC prodrug, was optimized through a nanoemulsion formulation (THCVHS-NE) for drug delivery into the eye and demonstrated significantly better reduction of intraocular pressure (IOP) compared to the commercially approved standard of care in normotensive rabbits.
Response was determined by measuring reduction in IOP from baseline following a single treatment with either THCVHS-NE (1% w/v), latanoprost (0.005% w/v), or timolol (0.25% w/v), which was measured every 30 minutes post-treatment up to 180 minutes, followed by measurements at 240, 360 and 480 minutes post-treatment. Duration of response was determined as the time required for IOP to return to 90% of baseline. THCVHS-NE achieved a maximum drop in IOP of 23% compared to latanoprost (13%) and timolol (14%). In addition, duration of response for THCVHS-NE was ≤480 minutes, compared to latanoprost (≤360 minutes) and timolol (≤90 minutes) (p<0.05) in normotensive rabbits. Therefore, a nanoemulsion formulation of THCVHS appears to not only be more effective at reducing IOP, but also has a longer duration of response when compared to standard of care treatment for glaucoma.
The article, entitled “Effect of surfactant concentration and sterilization process on intraocular pressure–lowering activity of Δ9 ‑tetrahydrocannabinol‑ valine‑hemisuccinate (NB1111) nanoemulsions,” authored by Sweeney, C., Dudhipala, N., Thakkar, R. et al, was published in the November 2020 issue of Drug Delivery and Translational Research. The experiments were conducted by researchers at the University of Mississippi.
“Our aim is to be able to offer ophthalmologists and their patients a superior new class of treatment for glaucoma, with better intraocular-pressure-lowering activity to prevent vision loss. The intriguing scenario is that THC’s ability to lower intraocular pressure is already validated – we know it works, based on prior human studies! We also know, however, that to successfully employ THC as a good medicine for glaucoma we need to have an effective method of local delivery into the eye, consistent with the American Academy of Ophthalmology’s recommendation against systemic use of cannabis to manage glaucoma. This is precisely what our drug offers,” said Punit Dhillon, CEO of Emerald.
“What is additionally and particularly notable is that our unique, synthetic bioengineered THCVHS molecule has potential capabilities that current treatments are unable to provide. A large percentage of glaucoma patients do not experience increased IOP but nevertheless experience vision loss believed to result from other neurodegenerative effects on the cells of the optical nerve. THC is also known to have neuroprotective properties. If our drug can protect against vision loss in patients with normal IOP as well, we would have an extraordinary new solution to offer for the prevention of glaucoma-related vision loss.
“We are working to complete our preclinical work in the near term and then start our planned human study in the third quarter of 2021. The nature of this disease will allow us to simultaneously provide safety and early efficacy outcomes in a first human study that is relatively fast and low-cost compared to the typical realization of such results in the clinical trial process,” added Mr. Dhillon.
Endexx Corporation (OTC: EDXC): Music magnate, mega producer and GRAMMY® Award-winning artist DJ Khaled announced his entrance into the CBD industry. Inspired by his personal wellness journey, Khaled, in partnership with Endexx, a leading producer and manufacturer of hemp-derived CBD wellness products, will introduce his new company and debut the first collection in 2021.
Although most well-known for his contributions to the music world, the self-made businessman turned international music icon is also a dedicated family man -- committed to instilling the importance of health and wellness into everyday life. Grateful to be a father, he released two albums in honor of his children, Father of Asahd in 2019 and Grateful in 2017. With all of these blessings, Khaled continues building his legacy and success by focusing his energies on the health and wellness sector.
“As a father, an entrepreneur, a music exec and visionary I am blessed with daily inspiration, a drive to work hard and a passion for success. CBD has become a part of my daily routine and allows me to focus myself and my energies, while striving to better myself every day,” says DJ Khaled. “I was drawn to Endexx Corporation because they're an innovative company that has proven they have the keys to deliver consistent, top of the line, high-quality products.”
“We are excited to announce our partnership with DJ Khaled,” stated Todd Davis, CEO of Endexx Corporation. “Khaled’s knowledge and passion for CBD is bountiful and we realized we are aligned in our approach towards product quality and business acumen. We understand and share the values that a brand goes beyond physical products; it needs to help people feel good about themselves and be part of a day-to-day lifestyle.”
Miami based IMPACT Brokers, the third party in the joint venture, will be spearheading sales and integrated marketing efforts on behalf of the brand. “We are committed to accelerating innovation and diversity throughout this developing industry while offering strategic guidance to best-in-class CBD suppliers. IMPACT Brokers sits at the forefront of culture and has the ability to predict industry trends. We look forward to taking this newest business nationwide,” says Ryan Stender, CEO of IMPACT Brokers.
The hemp-derived, cannabidiol-rich collection is anticipated to launch in early 2021.
Item 9 Labs Corp. (OTCQX: INLB), a vertically integrated cannabis operator that produces premium products, announced today that it has finalized its merger agreement with ONE Cannabis Group (OCG, Inc.) and expects to close the merger in January 2021.
ONE Cannabis Group, based in Colorado, is the parent company to the cannabis dispensary franchise Unity Rd. Built up from the legacy of a 10-plus year, award-winning Colorado dispensary & cultivator and infused with decades of franchise experience, the company helps eager operators enter the complex industry with ease. The cannabis franchise pioneer offers its partners the knowledge, resources, and ongoing support needed to compliantly and profitably operate a dispensary. Currently, Unity Rd. has franchise agreements signed for the development of more than two dozen shops across multiple states and expects the first store to open in quarter one 2021.
Recently, it was named one of the top cannabis retail leaders in the nation by MJBizDaily magazine and one of the "Best Cannabis Companies to Work For" in both the dispensary and cultivation categories in Cannabis Business Times' elite 2020 list. The company is also the first cannabis business to earn a Franchise Times Dealmakers award – a recognition presented to the boldest players driving mergers and acquisitions in franchising. For more information on ONE Cannabis Group, visit ocginc.com and head to unityrd.com for details on the Unity Rd. franchise opportunity.
"Our teams have been working on parallel paths to ensure a smooth integration and are eager to officially operate as one unit. This was a significant milestone for all and we look forward to closing [the merger] in January 2021," Item 9 Labs' Chief Executive Officer, Andrew Bowden, commented. "The merger with ONE Cannabis Group greatly enhances our business capabilities with its retail distribution and unique franchise operation. Their business model and national network of Unity Rd. franchise partners create highly predictable, recurring revenue streams."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Tuesday, December 15, 2020
Investor Ideas #Potcasts #Podcast - Episode 507, #Cannabis News and #Stocks on the Move: (CSE: $PULL.C) (OTCQB: $DRVD) (CSE: $HOLL.C) (CSE: $STEM.C)
Investor Ideas #Potcasts #Podcast - Episode 507, #Cannabis News and #Stocks on the Move: (CSE: $PULL.C) (OTCQB: $DRVD) (CSE: $HOLL.C) (CSE: $STEM.C)
Delta, Kelowna, BC, December 15, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/121520-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/12151PULL-DRVD-HOLL-STEM.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be looking at a few private and public company announcements.
Pure Extracts Technologies Corp. (CSE: PULL), a plant-based extraction company focused on cannabis, hemp, and the rapidly emerging functional mushroom sector, announced their support of Health Canada’s proposed intent to revise the Special Access Programme (SAP) and related regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments. The intended SAP revision, announced on December 11th, could lead to important new medical applications, particularly in the complex and growing mental health sector.
Health Canada’s announcement could act as a milestone achievement driving advanced research initiatives forward. This includes several ongoing clinical trials that consistently indicate breakthrough therapy potential of psilocybin-assisted psychotherapy for a number of mental health patients suffering from conditions where conventional therapies have failed or have proven unsuitable.
The proposed SAP update emphasizes the strategic importance of Pure Extracts engagement of a globally recognized operations, compliance, and regulatory consulting firm to advise on the Company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (CDSA). The CDSA and its Regulations provide the framework for legal access to controlled substances, and the control and regulation of production, distribution, and sale. One of Health Canada’s responsibilities is to provide the licensing and oversight framework for the legal production of controlled substances.
Upon acceptance, a Dealer’s License could allow Pure Extracts to engage in the following activities:
● Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
● Research and manufacture of controlled substances such as psilocybin and psilocin
● Business to business sale of controlled substances, including by export
● Sale of controlled substance via pharmacies
Expanding upon the strategic importance of the SAP review, Pure Extracts recently announced a collaboration with Dr. Alexander MacGregor as a key scientific advisor to the Company. Pure Extracts and Dr. MacGregor are collaborating on the development and research of optimum psilocybin extraction methodologies in preparation to service the needs of the rapidly advancing growth and demand in the sector.
As previously noted, Dr. MacGregor is the Dean of Faculty, a distinguished Professor of Biopharmaceutics, and current President of the Toronto Institute of Pharmaceutical Technology (TIPT) – North America’s premier post-graduate institute of pharmaceutical sciences, technology and research. He is also the CEO of TIPT’s parent company, Transpharm Canada Inc., which holds a Health Canada Drug Establishment License, a Cannabis Drug License, and a Dealer’s License issued under the Controlled Drugs and Substances Act (CDSA). Transpharm Canada conducts clinical trials, drug development and is licensed to possess psychedelic drug compounds.
Pure Extracts CEO Ben Nikolaevsky states, “The Special Access Programme may prove to be the tipping point and fundamental milestone event that eventually transforms an entire segment of the medical community’s outlook towards the treatment of mental health conditions. With greater and more open access to trials, researchers can move towards larger and more comprehensive studies eventually including thousands of patient candidates. Through multiple large-scale studies, we see great promise in determining treatment safety, efficacy, and desired outcomes. Our research suggests a broad spectrum of products encompassing multiple formulations will be required to service demand across potentially intensive therapies through to microdosing protocols. Exact formulations and high-quality products will be required, and that is fundamentally the sort of work we understand and excel at. Here at Pure Extracts, we believe in the future of the mushroom-based drug development sector and are committed to building value based on the growing number of positive indicators for future success.”
Driven Deliveries, Inc. (OTCQB: DRVD), one of California's fastest-growing e-commerce cannabis retailers and direct-to-consumer logistics companies, today announced it has secured preliminary approval for a new e-commerce delivery hub in the Fresno County region. Driven has also submitted its application for this new cannabis non-storefront retail license to the State of California which is expected to be approved in the near-term. Plans for Driven's acquisition by Stem Holdings, Inc. (OTCQX: STMH) (CSE: STEM) later this month are continuing on schedule, creating Driven By Stem trading under Stem's current symbols.
This new strategically-located hub will enable Driven to serve central California with greater efficiency and speed, and will be led by key experienced employees transferring to this location to ensure a smooth and flawless launch. This is expected to create 50 new jobs in the local area and afford significant cost savings in both general and administrative costs, as well as local taxes, with savings of $1.2 million annually vs. servicing this market from a remote hub.
"Securing a license in Central California is a key component in Driven's focus on building market share with increasing operational efficiencies in new and current markets," commented Salvador Villanueva, interim CEO of Driven, and founder of its Budee e-commerce brand acquired earlier this year. "Our focus on expanding our footprint in California with our Budee and Ganjarunner e-commerce stores as well as new markets will be the key to driving profitability in 2021," he concluded.
"We are pleased that this first step in our plan to integrate Driven into Stem's operations is nearing completion," stated Adam Berk, CEO of Stem Holdings. "Sal and the team have made great strides over the last 60 days as part of our 'On Your Mark' initiative to prepare for a seamless assimilation of Driven that will quickly build value for our shareholders," he remarked.
Driven currently has delivery hubs located in Oakland and Los Angeles, California, and will be expanding to the Oregon market in which Stem already operates by year-end.
Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) has its roots in the birthplace of the American biker, and Easyriders has been the definitive voice of motorcycle culture for half a century. As part of Easyriders' 50th-anniversary celebration, the Company signed an exclusive agreement with Hollister Biosciences to introduce a national line of cannabis products that embody the biker spirit and ethos. It is anticipated that the new line will make its debut next month with pre-rolls and mini pre-rolls, followed by a cannabis tattoo balm that's applied directly to the skin after new ink, with a full line of products coming in 2021.
The Company feels the market potential for these products is significant, but so is the cultural significance considering the two companies involved.
Easyriders magazine debuted shortly after the groundbreaking 1969 film Easy Rider in which Peter Fonda and Dennis Hopper portray bikers traveling across the American Southwest. Similarly, Hollister Biosciences is based in Hollister, California, home to an infamous 1947 biker rally that birthed the outlaw biker image and inspired the Marlon Brandon film The Wild One. Cannabis, which had developed its own outlaw culture a few decades before, became a staple among bikers in the late '60s onward. As epitomized in the pages of Easyriders, this vibrant biker culture grew beyond its outlaw origins to inspire an independent spirit that embraces exploration, Americana and the sense of freedom that only comes from riding.
This is a culture that accepts nothing less than total authenticity. That includes its choice in cannabis, and that is why Hollister Biosciences and Easyriders were destined to take this ride together. From their historic roots in biker culture to their embrace of its visual iconography, these companies will offer the first truly authentic cannabis products for one of the most iconic cultures in modern American history.
"My vision for Hollister has always been to pay homage to the amazing biker culture that has permeated the global landscape over the past few decades by combining it with amazing cannabis products," says Carl Saling, the Co-Founder, CEO and Director of Hollister Biosciences. "Easyriders is one of the most iconic and recognizable global biker brands. We are proud to be their exclusive cannabis partner, and we look forward to producing a truly authentic experience across the cannabis SKUs we develop and distribute across America."
Hollister Biosciences, whose products are currently found in nearly 300 dispensaries in California and more than 80 in Arizona, takes a seed-to-shelf approach that carefully scales up small-farm style production that meets the highest quality standards. As part of the new agreement, the company will introduce Easyriders pre-rolls and tattoo balms into the California market in early 2021 with a full line of products to follow. Like an eastbound ride on Route 66, Arizona comes next, and the rest of the American markets will follow.
Pepper Foster, President of Easyriders, stated, "My vision for Easyriders has been to pay homage to the 50 years of this iconic magazine and to Joe Teresi who launched Easyriders in the late 1960s. The first magazine hit the stands in June 1970, and 50 years later, we are proud to carry the torch, expanding upon that yen to be devoid of restraint by taking a broader look at what it means to be a biker in the 21st century while staying connected to our original roots. In continuing our commitment to authenticity, we are proud and excited to partner with another iconic brand, Hollister. We invite you to take the ride with us. Ride hard. Ride fast."
The terms of the deal are; 2-year exclusive agreement on all cannabis products in the US with an 80:20 net revenue split in favour of Hollister with options to renew for subsequent terms.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Subscribe to:
Posts (Atom)